Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2016 (2016), Article ID 5362485, 6 pages
http://dx.doi.org/10.1155/2016/5362485
Case Report

Trazodone Addition to Paroxetine and Mirtazapine in a Patient with Treatment-Resistant Depression: The Pros and Cons of Combining Three Antidepressants

1Department of Psychiatry, Hospital do Divino Espírito Santo de Ponta Delgada, Avenida D. Manuel I, Ponta Delgada, 9500-370 Azores, Portugal
2Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
3Ciclo Básico de Medicina, Department of Biology, University of the Azores, Rua da Mãe de Deus, 9501-801 Ponta Delgada, Portugal

Received 7 July 2016; Revised 18 September 2016; Accepted 19 September 2016

Academic Editor: Bernardo Carpiniello

Copyright © 2016 Rui Lopes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Global Burden of Disease Study 2013 Collaborators, “Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013,” The Lancet, vol. 386, no. 9995, pp. 743–800, 2015. View at Publisher · View at Google Scholar
  2. F. Hardeveld, J. Spijker, R. De Graaf, W. A. Nolen, and A. T. F. Beekman, “Prevalence and predictors of recurrence of major depressive disorder in the adult population,” Acta Psychiatrica Scandinavica, vol. 122, no. 3, pp. 184–191, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. H. K. Kim, P. V. Nunes, K. C. Oliveira, L. T. Young, and B. Lafer, “Neuropathological relationship between major depression and dementia: a hypothetical model and review,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 67, pp. 51–57, 2016. View at Publisher · View at Google Scholar
  4. D. F. Ionescu, J. F. Rosenbaum, and J. E. Alpert, “Pharmacological approaches to the challenge of treatment-resistant depression,” Dialogues in Clinical Neuroscience, vol. 17, no. 2, pp. 111–126, 2015. View at Google Scholar · View at Scopus
  5. M. T. Berlim and G. Turecki, “What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials,” European Neuropsychopharmacology, vol. 17, no. 11, pp. 696–707, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. M. T. Berlim and G. Turecki, “Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods,” Canadian Journal of Psychiatry, vol. 52, no. 1, pp. 46–54, 2007. View at Google Scholar · View at Scopus
  7. M. H. Trivedi, M. Fava, S. R. Wisniewski et al., “Medication augmentation after the failure of SSRIs for depression,” The New England Journal of Medicine, vol. 354, no. 12, pp. 1243–1252, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. A. J. Rush, M. H. Trivedi, S. R. Wisniewski et al., “Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report,” The American Journal of Psychiatry, vol. 163, no. 11, pp. 1905–1917, 2006. View at Publisher · View at Google Scholar
  9. National Institute for Health and Clinical Excellence, “Depression: the treatment and management of depression in adults (update),” Clinical Guideline 90, 2009, http://www.nice.org.uk. View at Google Scholar
  10. D. Taylor, C. Paton, and S. Kapur, The Maudsley Prescribing Guidelines in Psychiatry, John Wiley & Sons, London, UK, 12th edition, 2015.
  11. P. J. McGrath, J. W. Stewart, M. Fava et al., “Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STARD report,” The American Journal of Psychiatry, vol. 163, no. 9, pp. 1531–1541, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. A. A. Nierenberg, M. Fava, M. H. Trivedi et al., “A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STARD report,” American Journal of Psychiatry, vol. 163, no. 9, pp. 1519–1530, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. L. M. Martín-López, J. E. Rojo, K. Gibert et al., “The strategy of combining antidepressants in the treatment of major depression: clinical experience in spanish outpatients,” Depression Research and Treatment, vol. 2011, Article ID 140194, 8 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Wiggins, T. Balasubramanian, and A. Ferraro, “Hyponatraemia and confusion in a 70-year-old female when bupropion was added to dothiepin and escitalopram,” Australasian Psychiatry, vol. 23, no. 5, pp. 507–509, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Restifo, “Walking on thin ice: the use of triple antidepressant combinations in refractory melancholic depression,” Australasian Psychiatry, vol. 20, no. 2, pp. 134–137, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Jayaram and P. Rao, “Safety of trazodone as a sleep agent for inpatients,” Psychosomatics, vol. 46, no. 4, pp. 367–369, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. American Psychiatric Association (APA), Diagnostic and Statistical Manual of Mental Disorders: DSM-5, American Psychiatric Association, Arlington, Va, USA, 5th edition, 2013.
  18. M. E. Thase, “Antidepressant combinations: cutting edge psychopharmacology or passing fad?” Current Psychiatry Reports, vol. 15, no. 10, article 403, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. K. R. Connolly and M. E. Thase, “If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies,” Drugs, vol. 71, no. 1, pp. 43–64, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. L. L. Carpenter, S. Yasmin, and L. H. Price, “A double-blind, placebo-controlled study of antidepressant augementation with mirtazapine,” Biological Psychiatry, vol. 51, no. 2, pp. 183–188, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Ferreri, F. Lavergne, I. Berlin, C. Payan, and A. J. Puech, “Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone,” Acta Psychiatrica Scandinavica, vol. 103, no. 1, pp. 66–72, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. S. J. Thomas, M. Shin, M. G. McInnis, and J. R. Bostwick, “Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression,” Pharmacotherapy, vol. 35, no. 4, pp. 433–449, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. S. M. Stahl, C. Lee-Zimmerman, S. Cartwright, and D. A. Morrissette, “Serotonergic drugs for depression and beyond,” Current Drug Targets, vol. 14, no. 5, pp. 578–585, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. S. M. Stahl and N. Muntner, “Antidepressants,” in Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, S. M. Stahl and N. Muntner, Eds., chapter 7, pp. 284–369, Cambridge University Press, Cambridge, UK, 4th edition, 2013. View at Google Scholar
  25. A. Fagiolini, A. Comandini, M. C. Dell'Osso, and S. Kasper, “Rediscovering trazodone for the treatment of major depressive disorder,” CNS Drugs, vol. 26, no. 12, pp. 1033–1049, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. S. M. Stahl, “Mechanism of action of trazodone: a multifunctional drug,” CNS Spectrums, vol. 14, no. 10, pp. 536–546, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Maes, H. Westenberg, E. Vandoolaeghe et al., “Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine,” Journal of Clinical Psychopharmacology, vol. 17, no. 5, pp. 358–364, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Otani, K. Mihara, N. Yasui et al., “Plasma concentrations of trazodone and m-chlorophenylpiperazine at steady state can be predicted from those after an initial dose of trazodone,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 21, no. 1, pp. 239–244, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Lopes, J. Matias, and R. C. de Melo, “Trazodone-induced nocturnal enuresis,” Psychiatry Research, vol. 235, pp. 211–212, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Savarese, M. Carnicelli, V. Cardinali et al., “Subjective hypnotic efficacy of trazodone and mirtazapine in patients with chronic insomnia: a retrospective, comparative study,” Archives Italiennes de Biologie, vol. 153, no. 2-3, pp. 231–238, 2015. View at Google Scholar
  31. S. M. Stahl, Stahl's Essential Psychopharmacology: Prescriber's Guide, Cambridge University Press, Cambridge, UK, 5th edition, 2014.
  32. N. M. Davies, D. Gunnell, K. H. Thomas, C. Metcalfe, F. Windmeijer, and R. M. Martin, “Physicians' prescribing preferences were a potential instrument for patients' actual prescriptions of antidepressants,” Journal of Clinical Epidemiology, vol. 66, no. 12, pp. 1386–1396, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. E. W. Boyer and M. Shannon, “The serotonin syndrome,” The New England Journal of Medicine, vol. 352, no. 11, pp. 1112–1120, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Fabbri and A. Serretti, “Pharmacogenetics of the efficacy and side effects of antidepressant drugs,” in Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders, K. J. Rybakowski and A. Serretti, Eds., pp. 39–54, Springer, Cham, Switzerland, 2016. View at Google Scholar
  35. J. Henssler, T. Bschor, and C. Baethge, “Combining antidepressants in acute treatment of depression: a meta-analysis of 38 studies including 4511 patients,” Canadian Journal of Psychiatry, vol. 61, no. 1, pp. 29–43, 2016. View at Publisher · View at Google Scholar · View at Scopus
  36. M. E. Thase, “Preventing relapse and recurrence of depression: a brief review of therapeutic options,” CNS Spectrums, vol. 11, no. 12, supplement 15, pp. 12–21, 2006. View at Google Scholar · View at Scopus
  37. S. D. Targum, “Identification and treatment of antidepressant tachyphylaxis,” Innovations in Clinical Neuroscience, vol. 11, no. 3-4, pp. 24–28, 2014. View at Google Scholar · View at Scopus